Why the study?
Concomitant use of the four guideline-directed HFrEF drug classes at target doses is often limited in clinical practice by intolerance or fear of complications.
Answers are grounded in this paper and cite their sources.
This practical guide provides strategies for initiating and modifying guideline-directed medical therapy in HFrEF patients with challenging clinical scenarios to prevent unnecessary down-titration or cessation of life-saving medications.
According to the 2021 European Society of Cardiology guidelines, the four pillars of medical therapy in heart failure with reduced ejection fraction (HFrEF) include sodium-glucose co-transporter-2 inhibitors, beta-blockers, mineralocorticoid receptor antagonists, and angiotensin-converting enzyme inhibitors or angiotensin receptor-neprilysin inhibitors. However, in clinical practice, concomitant use of all four drug groups in target doses is often limited by their intolerance or fear of potential complications. Herein, we present strategies to initiate or modify HFrEF therapy in frequent but challenging clinical scenarios (symptomatic hypotension, atrial fibrillation, kidney disease or worsening renal function, hyperkalemia) in a way that does not lead to unnecessary reduction or cessation of life-saving treatment.
No takes yet. Share an insight, caveat, or question.
Kapłon‐Cieślicka et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: